Correction of endocrine complications of oncoimmunotherapy
Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2023-04-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://www.omet-endojournals.ru/jour/article/view/12828 |
| _version_ | 1797204560387768320 |
|---|---|
| author | E. A. Pigarova A. S. Shutova L. K. Dzeranova |
| author_facet | E. A. Pigarova A. S. Shutova L. K. Dzeranova |
| author_sort | E. A. Pigarova |
| collection | DOAJ |
| description | Over the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment. |
| first_indexed | 2024-03-08T09:12:35Z |
| format | Article |
| id | doaj.art-cbbf2cbfe27541cf9aaffb38dac00f8b |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2024-04-24T08:37:10Z |
| publishDate | 2023-04-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-cbbf2cbfe27541cf9aaffb38dac00f8b2024-04-16T16:16:14ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242023-04-0119441843010.14341/omet1282810958Correction of endocrine complications of oncoimmunotherapyE. A. Pigarova0A. S. Shutova1L. K. Dzeranova2Endocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreOver the years, immunotherapy with immune checkpoint inhibitors (ICI) has become an effective treatment for malignant neoplasms. However, checkpoints play a crucial role in immunological tolerance and prevention of autoimmune diseases. Interfering with this mechanism can cause immune-related adverse events (IRAEs) that affect multiple organs in the body. Endocrinopathies are among the most common IRAES associated with ICI therapy. Given the unique nature of adverse events caused by the use of ICI drugs, a multidisciplinary team approach is required to effectively manage patients, minimize complications associated with drug toxicity, and fully realize the therapeutic potential of this treatment method. Taking into account the difficulty of detecting nonspecific symptoms, the importance of follow-up and timely intervention in case of toxicity detection, regular clinical and laboratory monitoring is necessary, as well as informing patients and doctors about the variants of endocrine adverse events and their treatment. While non-endocrine IRAES often require discontinuation of immunotherapy and are usually resolved by immunosuppressive therapy with high doses of glucocorticoids, endocrine IRAES usually do not need discontinuation of ICI treatment and rarely require immunosuppressive therapy, but seldomly regress and therefore demand a long-term treatment.https://www.omet-endojournals.ru/jour/article/view/12828immune checkpoint inhibitorsendocrine autoimmune adverse eventshypophysitisadrenal insufficiencycentral diabetes insipidusthyroiditis, hypocalcemiahypoparathyroidismhyponatremiadiabetes mellituscancer immunotherapyipilimumabnivolumab |
| spellingShingle | E. A. Pigarova A. S. Shutova L. K. Dzeranova Correction of endocrine complications of oncoimmunotherapy Ожирение и метаболизм immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab |
| title | Correction of endocrine complications of oncoimmunotherapy |
| title_full | Correction of endocrine complications of oncoimmunotherapy |
| title_fullStr | Correction of endocrine complications of oncoimmunotherapy |
| title_full_unstemmed | Correction of endocrine complications of oncoimmunotherapy |
| title_short | Correction of endocrine complications of oncoimmunotherapy |
| title_sort | correction of endocrine complications of oncoimmunotherapy |
| topic | immune checkpoint inhibitors endocrine autoimmune adverse events hypophysitis adrenal insufficiency central diabetes insipidus thyroiditis, hypocalcemia hypoparathyroidism hyponatremia diabetes mellitus cancer immunotherapy ipilimumab nivolumab |
| url | https://www.omet-endojournals.ru/jour/article/view/12828 |
| work_keys_str_mv | AT eapigarova correctionofendocrinecomplicationsofoncoimmunotherapy AT asshutova correctionofendocrinecomplicationsofoncoimmunotherapy AT lkdzeranova correctionofendocrinecomplicationsofoncoimmunotherapy |